Peanut Oral Immunotherapy Efficacious in Allergic Adults
By Elana Gotkine HealthDay Reporter
THURSDAY, May 1, 2025 -- Peanut oral immunotherapy (OIT) is efficacious for adults with peanut allergy, according to a study published online April 23 in Allergy.
Hannah Hunter, from Guy's and St. Thomas' NHS Foundation Trust in London, and colleagues conducted a phase 2 trial to examine peanut OIT in peanut-allergic adults using real-world peanut products. Participants underwent baseline double-blind placebo-controlled food challenges (DBPCFC) with 0.3- to 300-mg doses of peanut protein. Participants who reacted were initiated on daily OIT with two-weekly updosing until a maintenance dose of 1,000 mg (four large peanuts) was reached. The proportion of OIT participants who tolerated a cumulative dose of 1.4 g peanut protein during exit DBPCFC was examined as the primary outcome.
The OIT group included 21 adults, with 67 percent achieving the daily maintenance dose and meeting the primary end point. The researchers found that three adults withdrew due to adverse reactions and three did not complete the trial for unrelated reasons. There was an increase in the median tolerated dose, from 30 mg to 3,000 mg at the exit challenge (about 1/8th to 12 peanuts). Improvement in quality-of-life measures was seen in association with OIT. In OIT, but not control participants, suppression of peanut skin-prick test sizes and induction of peanut-specific immunoglobulin G were observed.
"Peanut OIT can be an efficacious treatment for desensitization of adult peanut allergic patients," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Gluten-Free Diet for Celiac Disease Increases Arsenic Exposure in Children
FRIDAY, May 2, 2025 -- Children with newly diagnosed celiac disease have increased arsenic exposure shortly after transitioning to a gluten-free diet, according to a study...
Antibiotic Exposure Before Age 2 May Increase Risk for Chronic Pediatric Conditions
WEDNESDAY, April 30, 2025 -- Children receiving multiple antibiotic courses between birth and age 2 years may have a higher risk for some chronic conditions, according to a study...
Climate Change Tied to Alterations in Pollen Seasons, Concentrations
FRIDAY, April 11, 2025 -- Climate change seems to be altering pollen seasons and concentrations, potentially impacting allergic rhinitis, according to a review published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.